Menu

Pharmaceuticals

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer

, , ,

First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancer’s (SITC) 31 st Annual Meeting November 12, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s […]

Pfizer Announces Major Expansion of Humanitarian Assistance Program

, ,

Prevenar 13® Vaccine Will Be Available at Lowest Price for Humanitarian Emergencies Pfizer to Donate Sales Proceeds to Organizations Supporting the Refugee Crisis November 11, 2016 – Pfizer Inc. (NYSE:PFE) announced today a major expansion of its humanitarian assistance program enabling broader access to its vaccine, Prevenar 13, in humanitarian emergency settings by offering its […]

New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting

, ,

First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 Study November 7, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced […]

Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity

, , ,

First seven participants, through a combined 103 weeks of observation as of Aug. 4, 2016, did not need infusions of factor IX concentrates to prevent bleeding Updated SPK-9001 data in hemophilia B to be presented at the Plenary Scientific Session at 58th American Society of Hematology Annual Meeting November 3, 2016 – PHILADELPHIA and NEW […]

Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community

, ,

KENILWORTH, N.J. October 14, 2016 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of Biosimilars Clarified (www.merckclarifiesbiosimilars.com), a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines. Biosimilars are a type of biological […]

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress

, , ,

Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More) KENILWORTH, N.J. October 9, 2016 –(BUSINESS WIRE)– Merck (NYSE:MRK), known as MSD outside the United States and Canada, today […]

FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis

, , ,

Roche recently announced positive results from a Phase III GCA clinical trial Fourteenth Breakthrough Therapy designation for Roche medicines There have been no therapies approved for GCA in more than 50 years Basel, 05 October 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted […]

Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine​

, , ,

Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress Paris, France and Tarrytown, N.Y. (October 1, 2016) – Sanofi and Regeneron Pharmaceuticals, Inc. today announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies […]

Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek® in North America

, , ,

Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications DUBLIN, Ohio–(BUSINESS WIRE)–Sep. 6, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has executed a Letter of Intent (“LOI”) with Cardinal Health, Inc. (NYSE:CAH) for the sale of all rights, title and interest to Navidea’s Lymphoseek product for all FDA-approved, pending and […]

Danaher To Acquire Cepheid For $53.00 Per Share, Or Approximately $4 Billion

, ,

WASHINGTON, Sept. 6, 2016 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher” or the “Company”) announced today that it has entered into a definitive merger agreement with Cepheid (NASDAQ:CPHD) pursuant to which Danaher will acquire all of the outstanding shares of Cepheid for $53.00 per share in cash, or a total enterprise value of approximately $4 billion […]

«‹ 7 8 9 10›»